Organon & Co. (NYSE:OGN) Plans Quarterly Dividend of $0.28

Organon & Co. (NYSE:OGN - Get Free Report) declared a quarterly dividend on Thursday, May 2nd, Zacks reports. Shareholders of record on Monday, May 13th will be paid a dividend of 0.28 per share on Thursday, June 13th. This represents a $1.12 dividend on an annualized basis and a yield of 5.71%. The ex-dividend date is Friday, May 10th.

Organon & Co. Price Performance

Organon & Co. stock traded up $0.11 during trading hours on Friday, reaching $19.61. The company had a trading volume of 3,217,321 shares, compared to its average volume of 2,725,945. The company has a 50-day moving average price of $18.17 and a 200 day moving average price of $15.75. The firm has a market cap of $5.04 billion, a price-to-earnings ratio of 4.88, a P/E/G ratio of 0.89 and a beta of 0.81. Organon & Co. has a 12-month low of $10.84 and a 12-month high of $24.08.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its quarterly earnings data on Thursday, February 15th. The company reported $0.87 earnings per share for the quarter, topping analysts' consensus estimates of $0.73 by $0.14. The firm had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.55 billion. Organon & Co. had a negative return on equity of 212.00% and a net margin of 16.33%. As a group, research analysts expect that Organon & Co. will post 4.1 earnings per share for the current year.

Insider Buying and Selling at Organon & Co.

In other news, insider Kirke Weaver bought 2,720 shares of the stock in a transaction on Thursday, February 22nd. The shares were bought at an average price of $18.36 per share, with a total value of $49,939.20. Following the completion of the acquisition, the insider now owns 15,181 shares in the company, valued at $278,723.16. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.17% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

OGN has been the topic of a number of recent analyst reports. Piper Sandler lifted their price objective on Organon & Co. from $22.00 to $24.00 and gave the stock an "overweight" rating in a research report on Monday. The Goldman Sachs Group lifted their price objective on Organon & Co. from $18.00 to $20.00 and gave the stock a "neutral" rating in a research report on Friday.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.